- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01751867
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
April 1, 2016 updated by: Xian-Janssen Pharmaceutical Ltd.
An Open-label, Multi-center, Phase IIIb Study for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
The purpose of this study is to evaluate the effectiveness and safety of decitabine in the treatment of myelodysplastic syndrome (name of a group of conditions that occur when the blood-forming cells in the bone marrow are damaged) in Chinese patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective (look forward using periodic observations collected predominantly following patient enrollment), open-label (all people involved in the study know the identity of the assigned drug), Phase IIIb study to evaluate the efficacy and safety of decitabine in the treatment of myelodysplastic syndrome (MDS).
Patients are randomized (study drug assigned by chance) in 1:1 ratio to receive treatment with decitabine either 3-day or 5-day course of therapy.
When a minimum of 30 patients are reached for 3-day course of therapy, the rest of the patients will all be enrolled into 5-day course of therapy.
Each patient in the study treated for a minimum of 4 cycles; however, a complete or partial response may take longer than 4 cycles.
The entire study duration for each patient will be approximately two years.
Safety will be evaluated for each patient by monitoring of adverse events, physical examinations, vital signs measurements, electrocardiogram, hematology and clinical chemistry testing.
Study Type
Interventional
Enrollment (Actual)
135
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
-
Chengdu, China
-
Guangdong, China
-
Hangzhou, China
-
Nanjing, China
-
Shanghai, China
-
Suzhou, China
-
Tianjin, China
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have diagnosed with Myelodysplastic Syndrome (MDS) denovo (previously not present) or secondary as per the classification of French-American-British (FAB) and International Prognostic Scoring System (IPSS) greater than or eaul to 0.5 as determined by complete blood count (CBC), bone marrow assessment and bone marrow cytogenetics
- Must have an Eastern Oncology Cooperative Group (ECOG) performance status of 0-2
- Must have adequate hepatic and renal function as measured by the aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin and serum creatinine, respectively
- Must have recovered from all toxic effects of prior therapy and not received any chemotherapy for a minimum of 4 weeks (6 weeks if the patient has been treated with a nitrosoureas) prior to the first dose of study drug - Woman must be postmenopausal, or surgically sterile, or abstinent, or, if sexually active, be practicing an effective method of birth control (eg, oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization)
Exclusion Criteria:
- Must not have a diagnosis of acute myeloid leukemia (greater than 30% bone marrow blasts) - Must not have received radiotherapy within 14 days before the first dose of study drug - Must not have any other prior cancer, other than superficial bladder cancer, basal cell skin and cervical cancer - Must not have associated autoimmune hemolytic anemia or immune thrombocytopenia and inaspirable bone marrow - Must not have a mental illness or any other condition (eg, uncontrolled cardiac or pulmonary disease, diabetes), that could prevent full cooperation with the study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3-Day Dose schedule
Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days.
Cycles will be repeated every 6 weeks.
|
Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2.
Cycles will be repeated every 6 weeks.
|
Experimental: 5-Day Dose schedule
Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days.
Cycles will be repeated every 4 weeks.
|
Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR) - International Working Group (IWG) 2006 Response Criteria
Time Frame: From the date of first dose until 30 to 42 days after the last dose of the 2 years treatment period, or at time of discontinuation
|
IWG 2006 response criteria - CR: bone marrow evaluation shows less than or equal to (<=) 5% blasts; normal maturation of all cells lines (mCR), peripheral blood evaluation shows hemoglobin >= 11 gram per deciliter (g/dL), neutrophils >= 1000/mL, platelets >= 100,000/mL, 0% blasts; PR: Same as CR, except blasts decrease by >=50%, still greater than 5% in bone marrow.
|
From the date of first dose until 30 to 42 days after the last dose of the 2 years treatment period, or at time of discontinuation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematological Improvement Rate: Number of Participants Who Achieved Complete Remission (CR), Partial Remission (PR) and Hematologic Improvement (HI) - International Working Group (IWG) 2006 Response Criteria
Time Frame: From the date of first dose until 30 to 42 days after the last dose of the 2 years treatment period, or at time of discontinuation
|
IWG 2006 response criteria - CR: bone marrow evaluation shows <= 5% blasts; normal maturation of all cells lines (mCR), peripheral blood evaluation shows hemoglobin >= 11 g/dL, neutrophils >= 1000/mL, platelets >= 100,000/mL, 0% blasts; PR: Same as CR, except blasts decrease by >= 50%, still greater than 5% in bone marrow; HI: hemoglobin increase of >= 1.5 g/dL, platelet increase of >= 30,000/mL (starting with > 20,000/mL), neutrophils increase of >= 100% and > 500/μL.
|
From the date of first dose until 30 to 42 days after the last dose of the 2 years treatment period, or at time of discontinuation
|
Cytogenetic Response Rate: Percentage of Participants Who Achieved Cytogenetic Response (Complete+Partial) by Status of Clinical Overall Response - International Working Group (IWG) 2006 Response Criteria
Time Frame: From the date of first dose until 30 to 42 days after the last dose of the 2 years treatment period, or at time of discontinuation
|
As per IWG 2006 response criteria - Complete cytogenetic response: disappearance of the chromosomal abnormality without appearance of new ones; Partial cytogenetic response: At least 50% reduction of the chromosomal abnormality.
Status of Clinical response - complete remission (CR); marrow CR (mCR); partial remission (PR).
|
From the date of first dose until 30 to 42 days after the last dose of the 2 years treatment period, or at time of discontinuation
|
Transfusion Independence: Number of Participants Who Were Transfusion Independent
Time Frame: Baseline; up to 2 years
|
A participant was considered to be transfusion independent, if the participant had no transfusions of Red Blood Cells (RBCs) or platelets for 8 consecutive weeks or more.
|
Baseline; up to 2 years
|
Mean Percentage of Duration of Hospitalization (Relative to Days on Study Treatment)
Time Frame: Up to 2 years
|
Duration of hospitalization was calculated as, total number of days a participant stayed in hospital during study treatment divided by the study treatment duration
|
Up to 2 years
|
Overall Survival Rate: Percentage of Participants Who Survived During 6 Months and 12 Months of Treatment.
Time Frame: From the date of dosing until death or lost to follow-up for up to 2.5 years after last patient was enrolled
|
From the date of dosing until death or lost to follow-up for up to 2.5 years after last patient was enrolled
|
|
Mean Change From Baseline to End of Treatment in Scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ C-30) Physical Functioning Scale
Time Frame: Baseline to end of treatment (approximately up to 2 years)
|
EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients.
It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures.
For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much".
Higher scores indicate worsening.
The 2 single-item measure involves question about the overall health and overall quality of life which will be rated on a 7-point scale ranging from "1 = very poor" to "7 = excellent".
Lower scores indicate worsening.
Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.
|
Baseline to end of treatment (approximately up to 2 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Xian-Janssen Pharmaceutical Ltd Clinical Trial, Xian-Janssen Pharmaceutical Ltd.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
July 25, 2012
First Submitted That Met QC Criteria
December 13, 2012
First Posted (Estimate)
December 18, 2012
Study Record Updates
Last Update Posted (Estimate)
April 5, 2016
Last Update Submitted That Met QC Criteria
April 1, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR017443
- DACOGENMYE-3002 (Other Identifier: Xian-Janssen Pharmaceutical Ltd)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Thomas Jefferson UniversityAbbVieRecruitingMyelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic SyndromeUnited States
-
Uma BorateRecruitingTherapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic SyndromeUnited States
-
University Hospital, BrestRecruitingMyelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)France
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
Clinical Trials on Decitabine at 15 mg/m2
-
Janssen Pharmaceutical K.K.CompletedMyelodysplastic SyndromeJapan
-
University Hospital FreiburgCompletedAcute Myeloid LeukemiaGermany, Netherlands
-
Fundacion OncosurCompleted
-
University of Alabama at BirminghamSanofi; Astellas Pharma IncWithdrawn
-
University Hospital, GrenobleTerminatedKidney Transplantation | End-stage Renal Disease | Hla-incompatible Kidney Transplant CandidatesFrance
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
OnxeoCompletedCarcinoma, HepatocellularItaly, Spain, United States, Belgium, Austria, France, Egypt, Germany, Hungary, Turkey, Lebanon
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
-
Joseph JurcicBristol-Myers SquibbTerminatedMyeloproliferative NeoplasmUnited States
-
Chengdu Zenitar Biomedical Technology Co., LtdRecruitingStudy of Purinostat Mesylate for Injection in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma,DLBCLChina